CTLA4 and heterotaxy, visceral, 5, autosomal: As noted in the SIV-infection model, sodium butyrate supplementation did not provide immunological benefit in other murine cancer models, and its administration reduced the efficacy of anti-CTLA-4 therapy in these studies (56).